Neurological & CognitiveResearch OnlyS

Dihexa

PNB-0408

Dihexa (PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a potent hepatocyte growth factor (HGF) receptor agonist originally developed at Washington State University. Preclinical studies in rodents show it enhances synaptic connectivity and spatial memory retention — with reported potency millions of times greater than BDNF. No published human clinical trials exist. Research only; use with caution.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
4
Research grade
S
Community score
70

Trend index

Trackers
867

Overview

About Dihexa

Dihexa (PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a potent hepatocyte growth factor (HGF) receptor agonist originally developed at Washington State University. Preclinical studies in rodents show it enhances synaptic connectivity and spatial memory retention — with reported potency millions of times greater than BDNF. No published human clinical trials exist. Research only; use with caution.

Category
Neurological & Cognitive
Regulatory status
Research Only
Also known as
PNB-0408
Self-reports
19

Community

What 19 users report

19 community reports

Positive 2% · Neutral 98% · Negative 0%

Most reported benefits

Cognition
143

Dose distribution

Median: 2000+ mcg · Most common: 2000+ mcg

0–25
3
25–50
0
50–100
0
100–200
0
200–400
0
400–600
0
600–1000
0
1000–2000
0
2000+
140

How repeat users are trending

Among repeat reporters, 84% said they felt similar to their last entry, 16% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 141 days · Based on 19 repeat reporters

Research

Cited research (2)

PubMed

Dihexa, a small molecule that promotes new synapse formation, demonstrates cognitive enhancement

McCoy et al., 2013

Source
Wiki study page →

Help

Frequently asked

What do PeptIQ users report about Dihexa?

This page summarizes 19 anonymized self-reports from PeptIQ users who track Dihexa, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for Dihexa?

2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is Dihexa safe to use?

This wiki does not assess safety or recommend use. Dihexa is listed as Research Only. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of Dihexa?

Research, primarily in animal models, suggests Dihexa may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of Dihexa?

Dihexa is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Dihexa as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of Dihexa?

The safety and effectiveness of Dihexa have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on Dihexa?

While there are over 200 published studies on Dihexa, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source